Related Experiment Video

Updated: Mar 31, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K

Targeting leukemia's "fatty tooth"

Ismael Samudio1, Marina Konopleva2

  • 1CENTRE FOR DRUG RESEARCH AND DEVELOPMENT;

Blood
|October 17, 2015
PubMed

Insights

A new fatty acid oxidation (FAO) inhibitor, ST1326, effectively reduces leukemia cell growth, survival, and resistance to chemotherapy in laboratory studies. This discovery offers a potential new therapeutic strategy for leukemia treatment.

Area of Science:

  • Biochemistry
  • Oncology
  • Hematology

Background:

  • Leukemia is a cancer of blood-forming tissues.
  • Fatty acid oxidation (FAO) is a metabolic process crucial for cancer cell survival and proliferation.
  • Targeting cancer metabolism is a promising therapeutic strategy.

Purpose of the Study:

  • To investigate the efficacy of a novel fatty acid oxidation (FAO) inhibitor, ST1326, in leukemia.
  • To determine the effects of ST1326 on leukemia cell proliferation, survival, and chemoresistance.

Main Methods:

  • Treatment of leukemia cell lines and primary samples with ST1326.
  • Assessment of cell proliferation, viability, and response to chemotherapy agents.

Main Results:

  • ST1326 significantly inhibited proliferation and survival in leukemia cells.
  • ST1326 demonstrated effectiveness in overcoming chemoresistance in leukemia models.
  • The compound showed efficacy in both cell lines and primary patient samples.

Conclusions:

  • ST1326 is a potent inhibitor of fatty acid oxidation (FAO) with significant anti-leukemic activity.
  • ST1326 warrants further investigation as a potential therapeutic agent for leukemia, particularly in overcoming chemoresistance.

More Related Videos

Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS14:15

Preparation of Myeloid Derived Suppressor Cells MDSC from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting AutoMACS

Published on: June 18, 2012

27.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K